- Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy
-
So Young Han, Jeong Hun Bae, Jaeryung Oh, Hyeong Gon Yu, Su Jeong Song
-
Diabetes Metab J. 2015;39(1):46-50. Published online February 16, 2015
-
DOI: https://doi.org/10.4093/dmj.2015.39.1.46
-
-
3,726
View
-
36
Download
-
2
Web of Science
-
2
Crossref
-
 Abstract
 PDF PubReader
- Background
To evaluate the efficacy of intravitreal ranibizumab for subfoveal choroidal neovascularization (CNV) from age-related macular degeneration (AMD) with combined severe diabetic retinopathy (DR). MethodsThis retrospective, interventional case series included eleven patients (mean age, 70.09 years; range, 54 to 83 years) with at least severe non-proliferative DR and subfoveal CNV secondary to AMD. Each subject was treated with intravitreal injections of 0.5 mg ranibizumab. The primary outcomes included change in best-corrected visual acuity and central subfield thickness (CST) on optical coherence tomography (OCT). ResultsThe mean follow-up time was 16.7±14 months (range, 6 to 31 months). Mean visual acuity improved from 1.21±0.80 logarithm of the minimum angle of resolution (logMAR) to 1.0±0.6 logMAR (P=0.107), 0.95±0.62 logMAR (P=0.044), 1.10±0.68 logMAR (P=0.296), and 1.13±0.66 logMAR (P=0.838) at 1, 3, 6, and 12 months after injection, respectively. Eight patients (72.7%) gained or maintained vision (mean 0.32 logMAR), whereas three patients (27.3%) lost more than one line of vision (mean 0.51 logMAR). The mean OCT CST was 343.9±134.6 µm at baseline, and the mean CST at 1, 3, 6, 12 months after the injection was 367.8±172.1 (P=0.864), 346.2±246.2 (P=0.857), 342±194.1 (P=0.551), and 294.2±108.3 µm (P=0.621), respectively. ConclusionIntravitreal ranibizumab injection can be considered to be a therapy for the stabilization of subfoveal CNV secondary to AMD with combined severe DR. However, these patients might exhibit limited visual improvement after treatment.
-
Citations
Citations to this article as recorded by  - Comparative study of widefield swept-source optical coherence tomography angiography in eyes with concomitant age-related macular degeneration and diabetic retinopathy
Matthew Finn, Grace Baldwin, Itika Garg, Hannah E Wescott, Thomas Koch, Filippos Vingopoulos, Rebecca Zeng, Hanna Choi, Diane Sayah, Deeba Husain, Nimesh A Patel, Leo A Kim, Joan W Miller, David M Wu, Demetrios G Vavvas, John B Miller
British Journal of Ophthalmology.2024; 108(7): 963. CrossRef - Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy
Francesco Bandello, Federico Corvi, Carlo La Spina, Lucia Benatti, Lea Querques, Vittorio Capuano, Jonathan Naysan, Xuejing Chen, David Sarraf, Maurizio Battaglia Parodi, Eric Souied, K Bailey Freund, Giuseppe Querques
British Journal of Ophthalmology.2016; 100(12): 1611. CrossRef
- Current Concepts in Diabetic Retinopathy
-
Su Jeong Song, Tien Yin Wong
-
Diabetes Metab J. 2014;38(6):416-425. Published online December 15, 2014
-
DOI: https://doi.org/10.4093/dmj.2014.38.6.416
-
-
6,335
View
-
58
Download
-
39
Web of Science
-
36
Crossref
-
Abstract
PDFPubReader
For the past several decades, tremendous efforts have been made to decrease the complications of diabetes, including diabetic retinopathy. New diagnostic modalities like ultrawide field fundus fluorescein angiography and spectral domain optical coherence tomography has allowed more accurate diagnosis of early diabetic retinopathy and diabetic macular edema. Antivascular endothelial growth factors are now extensively used to treat diabetic retinopathy and macular edema with promising results. There remains uncertainty over the long term effects and the socioeconomic costs of these agents. -
Citations
Citations to this article as recorded by
|
KDA
